FDA Seeks to Revoke Tavneos Approval Over Manipulated Study Data

The FDA says it wants to withdraw its approval of the drug Tavneos, arguing that the approval was based on study data that was manipulated. The move raises a difficult question about whether patients should still be able to access the medication. The article notes that revoking approval is not a straightforward process. Because the case involves weighing patient access against the integrity of the approval decision, it has become a complicated regulatory matter.